Skip to main content

Market Overview

Aridis Pharma To Test Inhaled Antibody Cocktail In COVID-19 Variants

Share:
  • Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has added its inhaled AR-711 monoclonal antibody with a second antibody, AR-713, designed to neutralize newly emerging COVID-19 mutated variants. The company says that the cocktail referred to as AR-712 will provide broad coverage of all known high-risk strains.
  • Also, Aridis announced preclinical development services support from NIAID. The company is on track to initiate the program's Phase 1/2/3 trial in the second half of 2021.
  • AR-711 is being developed as a self-administered, at-home inhaled treatment for COVID-19 patients who are not yet hospitalized.
  • AR-711 and AR-713 are fully human immunoglobulin G1 monoclonal antibodies discovered from screening the antibody-secreting B-cells of convalescent SARS-CoV-2 virus-infected (COVID-19) patients.
  • Price Action: ARDS gained 10.3% at $8 in the premarket trading on the last check Tuesday.
 

Related Articles (ARDS)

View Comments and Join the Discussion!

Posted-In: Covid-19Biotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com